Read More
FDA approves first therapy for symptomatic tenosynovial giant cell tumor
Today, the U.S. Food and Drug Administration granted approval to Turalio (pexidartinib) capsules for the treatment of adult patients with symptomatic tenosynovial giant cell tumor (TGCT) associated with severe morbidity or functional limitations and not responsive to improvement with surgery.
Read More
>>Hollywood's Exotic Secret For Healthy Weight Loss
Read More
- Once-a-day antiretroviral medicine for children proven to be more effective at suppressing HIV
- Around 132 million COVID-19 vaccinations administered in the UK in 2021
- SARS-CoV-2 omicron variant may be less severe than the delta variant
- Study sheds light on how the immune system behaves during pregnancy
Subscribe to:
Post Comments (Atom)
0 Response to "FDA approves first therapy for symptomatic tenosynovial giant cell tumor"
Post a Comment